Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.56 |
| ▸ | DDB1 | Q16531 | 18/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26518244 | 1.00 | CRBN (0.56) | CRBNDDB1POLB | |
| SCHEMBL25818971 | 1.00 | CRBN (0.56) | CRBNDDB1POLB | |
| SCHEMBL26042988 | 0.88 | CRBN (0.41) | CRBNDDB1POLB | |
| SCHEMBL24832965 | 0.81 | CRBN (0.60) | CRBNDDB1POLB | |
| SCHEMBL25818988 | 0.81 | CRBN (0.53) | CRBNDDB1POLB | |
| SCHEMBL25074184 | 0.79 | CRBN (0.57) | CRBNDDB1POLB | |
| SCHEMBL25501664 | 0.79 | CRBN (0.57) | CRBNDDB1POLB | |
| SCHEMBL24670590 | 0.78 | CRBN (0.60) | CRBNDDB1POLB | |
| SCHEMBL25074141 | 0.78 | CRBN (0.60) | CRBNDDB1POLB | |
| SCHEMBL25074524 | 0.78 | CRBN (0.60) | CRBNDDB1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, LYN | CRBN 84/4885DDB1 462/4885POLB 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.